CLDX vs QDEL
Celldex Therapeutics, Inc. and QuidelOrtho Corp., side by side — 6 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | QDEL |
|---|---|---|
| Revenue | $1.5M | $2.7B |
| Net income | $-258.8M | $-1.1B |
| Gross margin | 87.1% | 46.7% |
| Net margin | · | −41.5% |
| Return on equity | −40.6% | −46.1% |
| Diluted EPS | −$3.90 | −$16.69 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | $-83.0M |
| Equity | $527.2M | $1.9B |
| Net debt / equity | · | 1.41× |
| Current ratio | 10.49× | 1.50× |
| Revenue CAGR 5y | −26.9% | 10.4% |
| Profit CAGR 5y | · | · |
QDEL bills 1767.1× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
6 years side by side
| Fiscal year | CLDX | QDEL |
|---|---|---|
| FY2025 | $1.5M | $2.7B |
| FY2024 | $7.0M | $2.8B |
| FY2023 | $6.9M | $3.0B |
| FY2022 | $2.4M | $3.3B |
| FY2021 | $4.7M | $1.7B |
| FY2020 | $7.4M | $1.7B |
Bottom line
| Fiscal year | CLDX | QDEL |
|---|---|---|
| FY2025 | $-258.8M | $-1.1B |
| FY2024 | $-157.9M | $-2.1B |
| FY2023 | $-141.4M | $-10.1M |
| FY2022 | $-112.3M | $548.7M |
| FY2021 | $-70.5M | $704.2M |
| FY2020 | $-59.8M | $810.3M |
6 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$2,728,655,000 | QDEL |
| FY2024 | −$2,775,880,000 | QDEL |
| FY2023 | −$2,990,917,000 | QDEL |
| FY2022 | −$3,263,643,000 | QDEL |
| FY2021 | −$1,693,949,000 | QDEL |
| FY2020 | −$1,654,282,000 | QDEL |
QDEL has reported the higher revenue in every one of these 6 fiscal years. The gap has widened since the earliest year compared.
6 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
QDEL's return on equity has been more volatile than CLDX's over the 6 comparable fiscal years — 41.8 percentage points of standard deviation against 6.8.
6 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CLDX and QDEL over these 6 fiscal years — CLDX led in 2 and QDEL in 4.
6 of 17 comparable fiscal years — a year missing data on either side is not counted.